This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026
by Ahan Chakraborty
PTGX, ALMS, ORKA and VNDA offer diverse psoriasis opportunities, spanning approved therapies, late-stage candidates and earlier-stage programs.
VNDANegative Net Change PTGXPositive Net Change ALMSNegative Net Change ORKANegative Net Change
biotechnology biotechs medical pharmaceuticals
TBPH Meets Q2 Earnings Estimates, to be Acquired by Zymeworks
by Zacks Equity Research
Theravance's Q2 earnings match estimates. Cost cuts and a $929 million Zymeworks deal follow ampreloxetine's discontinuation.
TBPHNo Net Change ZYMEPositive Net Change VTRSPositive Net Change
biotechnology biotechs
ANIP Tops Q2 Earnings, Stock Down on Cortrophin Sales View Cut
by Zacks Equity Research
ANI Pharmaceuticals tops Q2 earnings and sales estimates, but shares fall as the company cuts its 2026 Cortrophin Gel revenue outlook.
ANIPNegative Net Change LQDAPositive Net Change HRMYPositive Net Change
biotechs earnings medical
IMCR Jumps 21.2% in 3 Months as Kimmtrak Growth Fuels More Momentum
by Kanishka Das
Immunocore's 3-month gain reflects Kimmtrak growth and pipeline progress, but valuation and mixed signals temper the momentum case.
IMCRNegative Net Change BMYNegative Net Change MRKNegative Net Change
biotechs
Is IMCR Worth Buying as Kimmtrak Growth Meets a Premium Valuation?
by Kanishka Das
Immunocore's Kimmtrak growth and late-stage catalysts strengthen its case, but a premium valuation and single-product risk raise the stakes.
IMCRNegative Net Change BMYNegative Net Change LLYNegative Net Change
biotechs
IMCR Q2 Revenues Climb 18.3% as Kimmtrak Demand Helps Offset EPS Miss
by Kanishka Das
Immunocore's Q2 revenue beat reflects strong Kimmtrak demand, but an EPS miss and distributor stocking headwind cloud the near-term outlook.
IMCRNegative Net Change BMYNegative Net Change MRKNegative Net Change
biotechs
OTLK Up More Than 300% in 3 Months: Here's What You Should Know
by Zacks Equity Research
Outlook Therapeutics rallies 311.8% in three months as Lytenava's FDA approval boosts optimism ahead of its planned U.S. launch by year-end.
OTLKNegative Net Change RGENNegative Net Change LQDAPositive Net Change HRMYPositive Net Change
biotechs
Here's Why Replimune Stock Skyrockets Nearly 223% in 3 Months
by Zacks Equity Research
REPL's RP1 secures FDA approval for advanced melanoma, easing regulatory uncertainty. The company expands its oncolytic immunotherapy pipeline.
REPLPositive Net Change BMYNegative Net Change LQDAPositive Net Change HRMYPositive Net Change
biotechs
BMY Rallies 16.2% in Three Months: Buy, Sell or Hold the Stock?
by Ekta Bagri
Bristol Myers Squibb's Growth Portfolio and pipeline support momentum, but generic headwinds and recent gains call for a cautious stance.
BMYNegative Net Change PFENegative Net Change MRKNegative Net Change
biotechnology biotechs cancer medical pharmaceuticals
DNLI Q2 Loss Narrows, Avlayah Sales Drive Strong Launch Momentum
by Zacks Equity Research
Denali Therapeutics narrows Q2 loss as Avlayah sales top estimates, with strong launch traction and pipeline updates shaping its outlook.
DNLINegative Net Change BIIBPositive Net Change TAKNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals